1. On April 28, 2026, Zimmer Biomet reported Q1 2026 net sales of $2.087 billion, up 9.3% reported and 2.9% organic constant currency, with adjusted EPS of $2.09 up 15.5% year-over-year.
2. On April 7, 2026, the company appointed Dr. Jonathan M. Vigdorchik as Chief Science, Technology and Medical Affairs Officer.
3. On April 28, 2026, the company announced CFO Suketu Upadhyay will depart; Paul Stellato appointed Interim CFO.
4. In February 2026, the G7 Acetabular System received FDA 510(k) clearance and the first case was completed; the Phantom Curved TTC Nail System (Paragon 28) was launched for hindfoot fusion.
5. In March 2026, Zimmer Biomet fully launched ROSA Knee with OptimiZe at AAOS and showcased EMBOSS from Monogram Technologies.
Company Profile (Updated April 2026)
Zimmer Inc. is the wholly-owned subsidiary and core operating entity of Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), the world's leading medical technology company in musculoskeletal healthcare [^291^][^292^]. Zimmer Inc. is headquartered in Warsaw, Indiana, USA, the same location where the original Zimmer Manufacturing Company was founded on March 1, 1927 by Justin O. Zimmer and Joe N. Langston. Today, Zimmer Inc. serves as the primary operating vehicle through which Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive products, sports medicine solutions, biologics, and robotic surgical technologies to customers in 100+ countries.
Development History:
- 1927: Zimmer Manufacturing Company founded in Warsaw, Indiana, producing aluminum splints and fracture beds
- 1978: Acquired by Bristol-Myers, providing resources for national and international expansion
- 2001: Spun off from Bristol-Myers Squibb as an independent public company, trading on NYSE as ZMH
- 2003: Acquired Centerpulse AG, significantly expanding European hip market share and global footprint
- 2015: Zimmer Holdings completed the approximately $14 billion acquisition of Biomet, Inc., forming Zimmer Biomet Holdings, Inc. (ZBH) and creating the world's largest musculoskeletal healthcare company
- 2019: FDA cleared ROSA Knee robotic system, launching the company's robotics platform
- 2021: Launched ROSA Hip, expanding robotics into anterior hip replacement
- 2022: Spun off spine and dental businesses into ZimVie Inc. (Nasdaq: ZIMV), refocusing Zimmer Biomet on core joint reconstruction, sports medicine, and extremities
- 2024: Launched ROSA Shoulder for robotic shoulder replacement; acquired OrthoGrid Systems (AI surgical guidance) and Embody, Inc. (biologics)
- 2025 (April): Completed approximately $1.4 billion acquisition of Paragon 28, Inc., a leading foot-and-ankle orthopedic company, creating a dedicated foot-and-ankle sales channel
- 2025 (July): Announced acquisition of Monogram Technologies, developer of mBôs, a surgeon-guided autonomous robotic total knee arthroplasty system
- 2026 (Q1): Completed enrollment in India multi-center clinical study for mBôs autonomous robot; raised full-year adjusted EPS guidance to $8.40–$8.55
Core Mission: To alleviate pain and improve the quality of life for people around the world by advancing musculoskeletal healthcare through innovative products, integrated digital and robotic technologies, and data-driven surgical solutions.
2026 Financial Performance
First Quarter 2026 Results
Net Sales: $2.087 billion (up 9.3% reported; up 2.9% organic constant currency, excluding Paragon 28 and foreign currency impacts) [^233^][^239^]
Geographic Breakdown:
- United States: +3.2% growth; US Knee +2.2% (driven by >20% growth in Oxford Partial Cementless Knee); US Hip +5%
- International: +2.5% growth; impacted by distributor transitions in emerging markets, with mid-single-digit growth expected in H2 2026
Product Category Performance:
- Technology: 30% growth in Q1, driven by strong TMINI and ROSA sales
- Technology, Data, Bone Cement, and Surgical: Nearly 12% growth overall
- Paragon 28: First-quarter growth accelerated ~200 basis points from Q4 2025, trending back toward double-digit growth
Profitability:
- GAAP Diluted EPS: $1.22 (up 34.1%)
- Adjusted Diluted EPS: $2.09 (up 15.5%)
- Adjusted Gross Margin: 73.0% in Q1 (benefited from ~$0.20 tariff-related items); full-year expected around 71%
- Adjusted Operating Margin: 27.3%
- Free Cash Flow: $245.9 million
- Share Repurchases: $250 million completed in Q1
Full-Year 2026 Guidance
- Reported Revenue Growth: 2.5% to 4.5%
- Organic Constant Currency Revenue Growth: 1.0% to 3.0%
- Adjusted Diluted EPS: $8.40 to $8.55 (raised from prior $8.30–$8.45)
- Free Cash Flow Growth: 9% to 11% (raised from prior 8%–10%)
Core Products & Technology Platforms
Joint Reconstruction (Knees & Hips)
Knee Portfolio:
- Persona Knee System: Personalized implant system with anatomically matched components; company transitioning from legacy NexGen and Vanguard brands to Persona
- Persona OsseoTi: Cementless knee with porous titanium coating for biologic fixation
- Persona Revision SoluTion Femur: New revision knee implant component cleared by FDA in 2025
- Oxford Partial Knee: The only partial cementless knee on the U.S. market; grew >20% in Q1 2026
Hip Portfolio:
- Z1 Hip Stem: Represents nearly 40% of U.S. hip stems; part of the ＂hip triple play＂
- G7 Acetabular System: Next-generation implant for challenging primary and revision hip surgeries; FDA 510(k) cleared February 2026; first case completed Q1 2026
- OrthoGrid Hip Navigation: AI-based hip navigation platform
- HEMR Surgical Impactor: Part of the anterior hip triple play
Robotics & Digital Surgery
ROSA Robotics Platform:
- ROSA Knee (2019): Robotic assistant for total knee arthroplasty; now available with OptimiZe software and cementless compatibility (Persona OsseoTi)
- ROSA Hip (2021): Robotic system for anterior hip replacement
- ROSA Shoulder (2024): Robotic shoulder replacement system
- Enhanced Mixed Reality: New intra-op interaction capabilities debuted at AAOS 2026
Monogram / mBôs Autonomous Robot:
- mBôs: Surgeon-guided, autonomous robotic total knee arthroplasty system acquired from Monogram Technologies
- Status: Enrollment completed in 102-patient multi-center clinical study in India in Q1 2026
- Launch Timeline: Semi-autonomous version expected early 2027
- Sales Force Build: Targeting 200+ robotic clinical sales reps by end of 2027
EMBOSS: Fully autonomous AI-driven orthopedic robotic system from Monogram Technologies; surgeon feedback at AAOS 2026 was overwhelmingly positive
Smart Implants & Connected Technologies
Persona IQ Smart Knee:
- World's first smart knee implant with integrated Canary canturio te sensor technology
- Collects post-op gait parameters and transmits objective kinematic data for remote monitoring
- Canary Quantiles Recovery Curves: Cohort-comparative analytics for surgeons to benchmark patient recovery
myMobility Platform:
- Digital patient engagement platform with Apple Watch integration; enrolled 100,000+ patients
- WalkAI: AI-powered recovery curves predicting 90-day gait speed and benchmarking against matched cohorts
- WalkAI Patient Progress: Smartphone app for patients to track recovery against peers
S.E.T. (Sports Medicine, Extremities, Trauma) & Foot/Ankle
- Paragon 28 Portfolio: Leading foot-and-ankle solutions acquired April 2025; includes Phantom Curved TTC Nail System launched February 2026 for hindfoot fusion
- Biomet Sports Medicine: Soft tissue repair, biologics, and extremities portfolio
- Trauma: Fracture fixation and joint replacement solutions
CMFT & Other Segments
- Craniomaxillofacial and Thoracic (CMFT): Face and skull reconstruction, chest fixation products
- Biologics: PUR Biologics (via HippoFi partnership), Embody collagen-based solutions, Avitus Bone Harvester
- Bone Cement: Comprehensive portfolio of surgical cements and accessories
Strategic Priorities & 2026 Outlook
Three Pillars
- People & Culture: Building the right talent in the right roles; global workforce reduction announced January 2026 to right-size the organization, with majority of layoffs outside Warsaw
- Operational Excellence: Expanding manufacturing into lower-cost geographies; reducing days of inventory on hand; accelerating SKU rationalization; targeting improved free cash flow conversion
- Innovation & Diversification: Investing in AI-enabled robotics, smart implants, and digital ecosystems; committed as exclusive orthopedic investor in the Mobility Revolution Fund (Deerfield Management + Hospital for Special Surgery collaboration)
U.S. Go-to-Market Transformation
- Transitioning from non-dedicated to dedicated sales force model
- 1099 (non-dedicated) sales force reduced from roughly 66% to slightly below 60%; specialized reps increased from 25% to about 30%
- Productivity improvements observed: average reps moving from ~7 cases/week to double-digit cases/week in transitioned territories
- Transformation on track for completion by end of 2027
Company Information
Corporate Overview
Legal Entity: Zimmer Inc. (wholly-owned subsidiary of Zimmer Biomet Holdings, Inc.) [^291^][^292^]
Parent Company: Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH)
Founded: March 1, 1927
Headquarters: 345 East Main Street, Warsaw, Indiana 46580, USA
Global Presence: Operations in 25+ countries; sales in 100+ countries
Employees: 17,000+ worldwide
Industry: Medical Technology / Orthopedic Reconstructive Devices / Surgical Robotics
2025 Revenue: Approximately $7.7 billion
Leadership
Chairman, President & CEO (Zimmer Biomet Holdings): Ivan Tornos
- Leads global strategy, go-to-market transformation, and innovation roadmap
Chief Science, Technology and Medical Affairs Officer: Dr. Jonathan M. Vigdorchik (appointed April 7, 2026)
- Oversees global end-to-end technology portfolio including AI, robotics, smart implants, and data; also oversees global medical education
Chief Financial Officer (Transition):
- Suketu Upadhyay: Announced departure April 28, 2026
- Paul Stellato (Interim CFO): Vice President, Controller and Chief Accounting Officer; 20+ years of financial and IR experience; instrumental in share repurchase program and recent acquisitions [^272^]
Chief Innovation, Strategy and Business Development Officer: Jehanzeb Noor (departed February 2025)
Chief Movement Officer (Campaign Ambassador): Arnold Schwarzenegger (＂You'll Be Back＂ campaign)
Recognition & Ethics
- FORTUNE's 2026 America's Most Innovative Companies
- Ethisphere's 2026 World's Most Ethical Companies (second consecutive year)
- Great Place to Work Certified (2024–2025): 74% of employees say it is a great place to work vs. 57% at typical U.S. companies
- EPA Green Power Partnership: Warsaw headquarters powered by 100% renewable energy since 2016
Competitive Landscape
Major Competitors
- Stryker Corporation: Diversified medtech with strong orthopedic, robotics (Mako), and neurotechnology portfolios
- Johnson & Johnson (DePuy Synthes): Global leader in orthopedics, spine, and surgical robotics (Velys)
- Smith+Nephew: Sports medicine, extremities, and orthopedic reconstruction
- Medtronic plc: Spine and surgical robotics (Stealth Autoguide)
- ConMed: Sports medicine and orthopedic surgery devices
- Arthrex: Privately held leader in sports medicine and arthroscopy
- Exactech: Joint replacement and spine solutions
Zimmer Biomet's Competitive Advantages
- Market Leadership: #1 global market share in large-joint reconstruction (hips and knees)
- Robotics Ecosystem: Comprehensive ROSA platform (Knee, Hip, Shoulder) plus upcoming autonomous Monogram robot
- Smart Implant First-Mover: Persona IQ with integrated sensor technology and remote monitoring
- Digital Integration: myMobility, WalkAI, OrthoGrid, and OrthoIntel creating data-driven episode of care
- Foot & Ankle Scale: Paragon 28 acquisition creates dedicated high-growth sales channel in one of musculoskeletal's fastest-growing specialties
- Global Scale: 100+ country sales footprint with manufacturing in U.S., Ireland, Switzerland, and Puerto Rico
Contact Information
Global Headquarters
Address: 345 East Main Street, Warsaw, Indiana 46580, USA
Phone: 1-800-348-2759
Website: www.zimmerbiomet.com
Investor Relations
Address: Zimmer Biomet Holdings, Inc. Investor Relations, 345 East Main Street, Warsaw, IN 46580, USA
Website: investor.zimmerbiomet.com
Keywords: Zimmer Inc,Zimmer Biomet,Zimmer Biomet Holdings,ZBH,orthopedic implants,knee replacement,hip replacement,ROSA robotics,ROSA Knee,ROSA Hip,ROSA Shoulder,Monogram,mBos,Persona IQ,smart implant,OrthoGrid,Paragon 28,foot and ankle,sports medicine,extremities,trauma,CMFT,Warsaw,Indiana,1927,Ivan Tornos,Jonathan Vigdorchik,G7 Acetabular System,OptimiZe,Phantom TTC Nail,AAOS 2026,FORTUNE Most Innovative Companies,Ethisphere
